# SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

> **NCT06325748** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Senti Biosciences** · enrollment: 21 (estimated)

## Conditions studied

- AML/MDS
- CD33 Expressing Hematological Malignancies
- FLT3 Expressing Hematological Malignancies

## Interventions

- **BIOLOGICAL:** SENTI-202

## Key facts

- **NCT ID:** NCT06325748
- **Lead sponsor:** Senti Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2026-02
- **Final completion:** 2040-08
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06325748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06325748, "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06325748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*